The past two quarters of 2018 brought a wealth of opportunities for global mobilization and national commitments around malaria. From the Commonwealth Heads of Government Meeting and Malaria Summit in London, through to the first Malaria World Congress in Melbourne and the UN General Assembly in New York, momentum has steadily grown as the year progressed. In Asia Pacific, a number of leaders are taking concerted actions towards the elimination goal as a critical component of regional development.
As countries increasingly focus on malaria elimination, many are also foreseeing a shift in health financing toward universal coverage in support of integrated health services. In this context, new financing models are being developed to fill the financing gap for elimination, such as ‘Blended Finance for Impact’ discussed below. Novel collaborations are also working to foresee bottlenecks and drive innovation, such as the Vector Control Platform for Asia Pacific (or VCAP), also discussed below. The last quarter of 2018 has also seen private sector partners stepping up to tackle tomorrow’s national elimination priorities, M2030 being a prime example.
We are grateful to all partners who are helping us broker the country-focused partnership platforms outlined in this latest Partners Update.
Dr Benjamin Rolfe
CEO, APLMA Secretariat
During the World Economic Forum on ASEAN held last month in Ha Noi, Viet Nam, two new initiatives to accelerate malaria elimination and improve health outcomes in Asia-Pacific were launched. For further details about ‘Blended Finance for Impact’ and ‘M2030’ you can read our blog post summarizing the WEF meeting, read the WEF press release, watch the press conference that took place during the event, or read the article by Devex describing these regional malaria- and health-related developments.
The Asian Development Bank (ADB), the Global Fund and APLMA are working together to set up a new regional health fund under the Blended Finance for Impact initiative, a partnership to enable and increase long-term integrated financing for health, including malaria. Read articles by Christoph Benn (senior advisor to the Global Fund) and by Susann Roth/Aaron Batten (ADB) outlining the rationale for the initiative.
Hon. Rick Houenipwela, Prime Minister of the Solomon Islands, has reiterated his country’s commitment to end malaria for good by 2030. The PM’s remarks came during a high-level roundtable meeting on malaria that took place alongside the recent United Nations General Assembly. This renewed pledge builds on encouraging signs of progress against malaria in the Pacific nation. (Read more)
The APLMA Board of Directors met in October for their second semi-annual meeting of 2018. Please join us in thanking outgoing members of the Board for their contributions, and in welcoming new members. (Read more)
Yoma Strategic Holdings is set to lead the charge for the private sector to raise funds and awareness for malaria elimination in Myanmar. The company will spearhead private sector engagement for ‘M2030’, a regional movement that aims to accelerate progress against malaria and eliminate the disease in the region by 2030. Read the Yoma/APLMA media release.
The Asia Pacific Malaria Elimination Network (APMEN) partners and working groups developed concrete plans for country needs assessments and the prioritization of working group activities. Proof-of-Concept studies, new tools for surveillance including case-based surveillance, and rolling out of Organizational Development for Malaria Elimination (ODME) strategy in Asia Pacific are underway. (Read more)
The newly established Vector Control Platform for Asia Pacific (VCAP) held a consultation meeting alongside the annual APMEN business meetings to agree on priority activities for VCAP aimed at boosting innovation and improving access to vector control tools in the region. (Read more)
In many endemic countries, poor-quality antimalarial medicines continue to threaten malaria elimination efforts and put lives at risk. APLMA is working with partners towards a call to action for more regional collaboration against fake medicines. The Oxford Statement issued at the first conference on Medicine Quality and Public Health was a positive step in that direction, building on unprecedented global momentum. (Read more)